Introduction {#sec1-1}
============

Physiological functions of the body will be governed by three *Doshas*, that is, *Vata*, *Pitta*, and *Kapha*. Vitiation of these *Doshas* leads in disease manifastation. In old age there is progressive decaying in the body structures resulting in various degenerative disorders including *Sandhigatavata* due to the predominance of *Vata*.\[[@ref1]\] Osteoarthritis\[[@ref2]\] (OA) of modern medical science is considered to be its close equivalent.\[[@ref3]\][@ref4]\] According to a survey, osteoarthritis tops all the ailments in the country. In India, the prevalence is more among women, especially menopausal women.\[[@ref5]\] The current pharmacological management of osteoarthritis includes the administration of analgesics and Non Steroidal Anti-Inflammatory Drugs (NSAIDs), but their use neither provides adequate pain relief nor deceleration in disease process. In addition, NSAIDs are associated with adverse effects.\[[@ref6][@ref7]\] Due to which the use of alternative therapies is on the rise. The plan of the treatment in the study is based on the recommendations from classics for the treatment of *Vatavyadhi* (diseases essentially caused by *Vata*). A multimodal therapy in treating a disease is usual Ayurvedic therapy and it is being used in P.D. Patel Ayurved Hospital, Nadiad, since many years, providing good relief to the patients with *Sandhigatavata*. *Yogaraja Guggulu* and *Ashvagandha Churna* have reported to be beneficial in the management of *Sandhigatavata* (OA).\[[@ref8]\] The objective of the present study is to evaluate efficacy of multimodal Ayurvedic management for *Sandhigatavata*.

Materials and Methods {#sec1-2}
=====================

Fifty clinically diagnosed patients of *Sandhigatavata*, involving knee *joints*, were selected from the Outdoor Patient Department (OPD) and hospitalized for a duration of 15 days in the Department of Kaya Chikitsa, in between December 2010 to July 2011. Special clinical proforma was prepared and findings were recorded at regular interval for proper assessment. The enrolled patients were advised to withdraw use of NSAIDs before starting the Ayurvedic management.

The patients were assessed before treatment and after the completion of 15 days of indoor treatment. After completion of indoor treatment, the patients were administered oral medicines. Follow-up with full clinical assessment was done after 15 days and 45 days.

Inclusion criteria {#sec2-1}
------------------

Individuals between the age group of 30 to 75 years of both genders having clinical features of *Sandhigatavata* as described in Ayurvedic classics,\[[@ref9]\] as well as clinical features of osteoarthritisPatients with affection of knee joint, presenting with *Sandhishotha* (swelling over joints), *Sandhishula* (pain in joints), *Sandhigraha* (stiffness in joints), *Sprarshasahatva* (tenderness), and *Sandhisphutna* (crepitus)\[[@ref9][@ref10][@ref11][@ref12]\]Availability of at least 80% of the clinical features in patients was considered as an inclusion criteria for the present study. Radiology of the affected joints was not carried out because those patients who were included in the study have already been diagnosed radiologically.

Exclusion criteria {#sec2-2}
------------------

Patients below 30 years and above 75 years of agePatients suffering with other forms of arthritis like Rheumatoid Arthritis (RA), psoriatic arthritis, gout, ankylosing spondylitis, infective arthritis, and Systemic Lupus Erythematosus (SLE)Patients who had an association with other diseases like diabetes mellitus, hyper or hypothyroidism

Management of the patients {#sec2-3}
--------------------------

*Mriduvirechana* (mild purgation) with *Eranda Sneha* (seed oil of *Ricinus communis* Linn.), 30 -- 35 ml, according to the *Koshtha*, with warm water, was administered on the third day after admission following *Abhyanga* and *Svedana* for two days. *Koshtha* was assessed on the basis of the patient\'s bowel habits and sensitivity. Patients of *Mridu Koshtha* were given 30 ml of *Eranda sneha* and patients of *Madhyama* and *Krura Koshtha* were given 35 ml of it. After a rest for one day, the following therapies and medicaments were administered*Abhyanga* (oleation therapy) with *Narayana Taila* (*Vata* alleviating medicated oil)\[[@ref13]\] for 11 days.*Bashpasvedana* (fomentation therapy with evaporation) with *Nirgundipatra*\[[@ref14]\] (fresh leaves of *Vitex nigundo* Linn.) for 11 days*Nirgundipatra Upanaha* was done for 11 days*Niruha Basti* (proctocolonic administration of decoction) of *Dashamula Kvatha* (decoction of *Dashamula*) for one day (before lunch following *Abhyanga* and *Svedana*) followed by *Matra Basti* of 40 ml *Narayana Taila* (immediately after supper) was given for nine days*Yogaraja Guggulu*,\[[@ref15]\] 1 g, thrice a day, with warm water*Ashvagandha Churna* (root powder of *Withania somnnifera* Dunal.) 3 g with warm milk was given in morning and evening before meals*Jalaukavacharana* (leech application) was done on the patients on the eleventh day, if pain and stiffness were not relieved after *Snehana*, *Svedana*, *Mriduvirechana*, and *Basti*. This was repeated if required on the fifteenth day.

All formulations like *Narayana Taila*, *Eranda Sneha*, *Dashamula Kvatha*, *Yogaraja Guggulu*, and *Ashvagandha Churna* were prepared as per the standard guidelines under the supervision of the subject experts. Fresh leaves of *Nirgundi* were collected from the medicinal plant garden in the campus.

Pathyapathya (food regimen and behavioral advice) {#sec2-4}
-------------------------------------------------

On the day of *Mriduvirechana*, the patients were kept on semi-liquid recipe containing equal quantity of rice and mung beans in the evening. After this, patients were kept on usual food recommended by classics for the patients of *Vata* related diseases, that is, *Mudgayusha* (mung bean soup), chapatis of wheat flour, boiled vegetables, and rice. They were instructed not to take sour, fermented, or spicy food and to avoid *Atishrama* (heavy work), *Ratrijagarana* (night vigils) and *Divasvapa* (daytime sleep).

Criteria for assessment {#sec2-5}
-----------------------

The improvement was assessed with regard to the clinical features, on the basis of the scoring system \[Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}\].
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Subjective criteria
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Overall assessment of therapy
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Objective criteria {#sec2-6}
------------------

Improvement in range of movement was assessed before and after treatment with Goniometer.

Statistical analysis {#sec2-7}
--------------------

The improvement was assessed on the basis of relief in the clinical features of the disease before and after treatment. The obtained results were analyzed by Students paired '*t*' test.\[[@ref16]\] The results were interpreted as highly significant if *P* \< 0.001 and significant if *P* \< 0.05 or *P* \< 0.01.

Observations and Results {#sec1-3}
========================

The demographic data of this study suggested that osteoarthritis is prevalent in 97.22% of the menopausal women \[[Table 3](#T3){ref-type="table"}\]. It was observed that highly significant results were found in all clinical features \[[Table 4](#T4){ref-type="table"}\]. Highly significant results were found even after 15 days of treatment (first follow-up) with most of the features, while a significant result was found in the symptom of *Sandhisphutana* \[[Table 5](#T5){ref-type="table"}\]. It was observed that relief, in percentage, found in patients after 45 days (second follow-up) was almost the same as that taken on the first follow-up \[[Table 6](#T6){ref-type="table"}\]. Highly significant relief was found in flexion of the knee joint and significant relief in the extension of the knee joint \[[Table 7](#T7){ref-type="table"}\] and after 15 days (first follow-up) \[[Table 8](#T8){ref-type="table"}\]. It was observed that extension of the knee joint was improved to 26.88%, in comparison to the first follow-up (21.22%). The improvement in knee flexion movements was statistically highly significant. \[[Table 9](#T9){ref-type="table"}\]. It was observed that a minor difference was found in the mean scores of clinical features after 15 days of treatment as indoor patients and in both follow-ups \[[Figure 1](#F1){ref-type="fig"}\]. *Sprarshasahatva* was relived by 90.56% after 15 days of treatment, while 73.58% relief was found during follow-up \[[Figure 2](#F2){ref-type="fig"}\]. It was observed that a minor difference was found in the mean score of range of movement of the knee joint after 15 days and in followup \[[Figure 3](#F3){ref-type="fig"}\]. It was observed that the percentage of relief in extension of the knee joint was 41.03% after 15 days, which reduced in follow-up \[[Figure 4](#F4){ref-type="fig"}\]. In the present study, 24% had marked improvement after 15 days of treatment, which reduced by 16% after the first follow-up and by 14% after the second follow-up, while 50% of the patients had moderate improvement after 15 days, which increased by 52% during the period of both follow-up assessments \[[Figure 5](#F5){ref-type="fig"}\].
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Effect of therapy on clinical features after 15 days of indoor treatment
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Effect of therapy on clinical features during first follow-up
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Effect of therapy on clinical features second follow-up
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Effect of therapy on range of movement of knee joint after 15 days of indoor treatment

![](AYU-34-49-g007)

###### 

Effect of therapy on range of movement of knee joint during first follow-up
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Effect of therapy on range of movement of the knee joint during second follow-up
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![Comparison of mean scores in clinical features (knee joint osteoarthritis)](AYU-34-49-g010){#F1}

![Comparison of percentage improvement in clinical features (knee joint osteoarthritis)](AYU-34-49-g011){#F2}
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Discussion {#sec1-4}
==========

In the present study, it is observed that most of the female patients developed *Sandhigatavata* during the menopausal period. This supports estrogen deficiency as a risk of OA.\[[@ref17]\]

In present study, highly significant (*P* \< 0.001) effect was found in *Sandhishula*, *Sandhishotha*, *Sandhigraha*, and *Sandhisphutana* in both knee joints. This also supported a previous clinical study conducted, showing a marked reduction in pain and improvement in movements.\[[@ref18]\] The beneficial effect of *Abhyanga*, *Svedana*, and *Matrabasti* was also found reported.\[[@ref4]\]

Probable mode of action {#sec2-8}
-----------------------

### Mriduvirechana {#sec3-1}

Treatment of *Sandhigatavata* usually begins with a basic process like *Mriduvirechana*. It cleanses the body to restore patency of the *Srotasa*, which improve the access of healing material as well as nourishment to the body components. In addition, this also helps in maintaining or restoring the optimum equilibriumin Tridosha.

*Eranda Taila* is indicated for *Mriduvirechana* in *Vatavyadhichikitsa*.\[[@ref19]\] The *Eranda Beeja*, having *Vibhedana* (purgative), *Srotoshodhana* (channel-cleansing), and *Anulomana*, (directing *Vata* in the right direction) actions,\[[@ref20]\] is used for *Mriduvirechana*. *Eranda Taila* has *Vatahara*\[[@ref21]\] action and it is the best among the medicaments used for *Virechana* (purgative therapy).\[[@ref22]\] *Mriduvirechana* performed with *Eranda Taila* after *Purvakarma* (the preparatory procedures), that is, *Abhyanga* and *Svedana*, eliminates the *Dosha* from the body through *Koshtha*, without any complication.

### Abhyanga {#sec3-2}

*Taila* (oil) used in *Abhyanga* has *Snigdha* (unctuous), *Guru* (heavy), and *Mridu* (soft) properties, which are opposite to the properties of *Vata*. *Abhyanga* reduces the provoked *Vata*, which is responsible for the decay in the *Dhatus* and for manifestation of features like pain, stiffness, and crackes. According to modern studies, massage stimulates blood circulation and assists the lymphatic system, improving the elimination of waste throughout the body. Absorption through the skin can be enhanced by suspending the drug in an oily vehicle and rubbing it on the skin.\[[@ref23]\] Thus, the medicaments used as massage are absorbed through the skin.

### Svedana {#sec3-3}

*Svedana* is specially indicated in symptoms like *Sankocha* (contraction or flexion), *Ayama* (extension), *Shula* (pain), *Stambha* (stiffness), *Gaurava* (heaviness), and *Supti* (numbness).\[[@ref24]\] These are the usual clinical manifestations of *Sandhigatavata*. *Svedana* has actions like *Stambhaghna* (cures stiffness), *Svedakarakatva* (creates perspiration), *Gauravaghna* (cures heaviness), and so on.\[[@ref25]\]

### Nirgundipatra upanaha {#sec3-4}

*Upanaha* (poultice sudation) is a type of *Svedana* indicated in classics\[[@ref26]\] as one of the components in the treatment of *Sandhigatavata*.\[[@ref27]\] Studies have revealed the fact that lipid medium is highly suitable for penetration of the drug molecule through stratum corneum.\[[@ref28]\] On this basis, it can be assumed that the oil used in *Nirgundipatra Upanaha* serves as a lipoidal medium for penetration of the drug molecules of *Nirgundi* and exerts an immediate anti-inflammatory\[[@ref29]\] effect. Moreover heat applied with *Nirgundipatra upanaha* increases the local circulation and thus the rate of drug absorption. *Nirgundi* possesses *Vedanasthapana* (analgesic) and *Shothahara* (anti-inflammatory) actions.\[[@ref14]\] In most of the *Nighantus* it has been used for treating disorders characterized by *Shopha* (swelling) and *Shula* (pain).\[[@ref30]\] Its preventive effect on the development of formaldehyde-induced experimental arthritis has been observed.\[[@ref31]\] The present study supports these earlier observations and recommendations by the *Nighantus*.

### Niruha Basti {#sec3-5}

This *Basti* given for one day before *Matrabasti*, cleanses the colon and prepares a good atmosphere for the *Matrabasti* material to come in contact with the colon wall and exert its medicinal effect.

### Matrabasti {#sec3-6}

*Matrabasti* is a form of *Sneha Basti*. It is convenient and comfortable in administration. It nourishes the body, promotes the strength, and cures *Vata*-related diseases.\[[@ref32]\] *Basti*, through its action on *Vata* and *Agni*, promotes the formation of *Dhatus*. The colon is considered as main seat of *Vata*, and *Vata*-alleviating substances administered through the rectocolonic route in *Matrabasti* are able to have their optimum effect on the seat of *Vata*.

### Jalaukavacharana {#sec3-7}

Charaka Samhita mentions that if a disease does not respond to the application of opposite principles like *Shita--Ushna* (cold--hot) or *Snigdha -- Ruksha* (unctuous -- dry), vitiation of *Rakta Dhatu* must be considered.\[[@ref33]\] In such a condition *Raktamokshana* is one of the recommendations. Hence, in the present study *Raktamokshana* (blood-letting) has been done by applying *Jalauka* (leech) in 31 patients, as it is easy and does not produce complications. Although *Sandhigatavata* is essentially a *Vata*-disorder affecting the *Sandhi* structures, secondary involvement of the *Rakta Dhatu* is possible in these 31 patients, which is evident with the classical *Upashaya - Anupashaya* test described earlier. According to conventional medicine also, this is not purely a degenerative condition. This is why the earlier name osteoarthrosis is now accepted as osteoarthritis.

### Yogaraja Guggulu {#sec3-8}

It contains *Tridosha Shamaka* (pacifier of three *Doshas*, that is, *Vata*, *Pitta*, *Kapha*) and *Rasayana* (rejuvenative) actions and it is recommended for the management of all *Vata Rogas*.\[[@ref15]\] *Guggulu* possesses anti-inflammatory and analgesic actions. It helps in prevention against degenerative changes that may occur in bones and joints due to arthritis. *Guggulu* reduces inflammation and joint stiffness as well as pain associated with arthritis, and increases joint mobility.\[[@ref34]\] Earlier pharmacological studies on *Guggulu* have established its anti-inflammatory and anti-arthritic activities in formaldehyde-induced arthritis, in albino rats.\[[@ref35]\] Significant anti-inflammatory and anti-arthritic activities of oleo-gum resin has been reported against carragenun-induced rat paw edema, granuloma pouch, as well as adjuvant arthritis.\[[@ref36]\] A study presented at a recent meeting of the American College of Rheumatology, has shown that herbal Ayurvedic therapy consists of *Guggulu*, which is as effective in treating knee osteoarthritis as a commonly prescribed medication (Celebrex) and Glucosamine, and with fewer side effects. In addition, the *Guggulu* has been shown to be a potent inhibitor of the enzyme, Nuclear Factor Kappa-light-chain-enhancer of activated B cells (NFKB), which regulates the body\'s inflammatory response. There are several studies that show decreased inflammation and joint swelling after administration of the extracts of *Guggulu* resin.\[[@ref37]\]

### Narayana Taila {#sec3-9}

*Taila* (sesame oil) itself is a potent *Vata*-alleviating substance. Its *Vatashamaka* action is enhanced when it is processed with *Vatashamaka* drugs like *Patala* (*Stereospermum suaveolens* DC.), *Ashvagandha* (*Withania somnnifera* Dunal.), *Agnimantha* (*Clerodendrum phlomidis* Linn. f.), *Atibala* (*Sida cordifolia* Linn.), and the like, in preparing *Narayana Taila*. *Narayana Taila* can be administered through any route in *Vata Roga*.\[[@ref13]\] In current study, it is used for *Abhyanga* and *Matrabasti*.

### Ashvagandha Churna {#sec3-10}

It possesses *Shothahara* (anti-inflammatory), *Vatahara*, *Vedanasthapana*, *Shulaprashamana* (analgesic), and *Rasayana* (rejuvenative) actions.\[[@ref38]\] *Withania somnifera* (*Ashvagandha*), has shown a significant anti inflammatory activity.\[[@ref39]\] A study reported that an extract of the root powder of *Withania somnifera* has a chondroprotective effect on the damaged human osteoarthritic cartilage matrix in 50% of the patients tested.\[[@ref40]\]

In this clinical trial a majority of patients, that is, 56% had a chronicity between one and five years, and were taking NSAIDs repeatedly. After starting the therapy, the patients did not need NSAIDs for symptomatic relief. In the assessment during the first outdoor follow-up it was observed that marked improvement was reduced in comparison to improvement found after 15 days of indoor treatment in the patients, while patients with moderate improvement remained the same in both the follow-up assessment periods \[[Figure 5](#F5){ref-type="fig"}\]. This shows that the indoor treatment consists of manual therapies and least activities, as indoor patients contributed to marked and faster improvement in the first fortnight, which reduced initially at home, due to the absence of manual therapies and possibly increased activities, but became steady later on.

It is an incurable, but manageable disease, which is why the repetitive use of manual therapies is needed for a long time.

No adverse reaction of any procedure or oral medicaments were found during treatment, either as inpatients or as outpatients.

Conclusion {#sec1-5}
==========

It can be concluded from the present study that *Sandhigatavata* is commonly found mostly in menopausal females. The present study reveals that multimodal Ayurveda treatment provided highly significant relief in Sandhigatavata of the knee joint. This also shows the importance of manual therapies. The improvement remains steady even after 45 days of outdoor treatment. This shows the stable efficacy of the treatment. It is noticed that relief of symptoms has been found in spite of stopping NSAIDs in the patients. *Sandhigatavata* is *Yapya* (manageable) in nature, so repetitive use of this therapy is needed. This therapy is safe and effective in the management of *Sandhigatavata*.
